All Activity

If you’re exploring casino platforms that balance classic vibes with modern play, https://aussiecasinoonline.com.au/casinos/rtg gives a solid overview of destinations powered by Real Time Gaming. These casinos are known for their wide range of pokies, engaging table games, and smooth, reliable performance across devices. What makes them appealing is not just the variety of games, but also user‑friendly interfaces and generally generous bonus offers that add extra value to your play. Whether you’re chasing big wins or just want a fun, straightforward gaming experience, this collection of RTG sites is worth checking out if you enjoy diverse gameplay and trusted platforms.

I’m going to read this. I’ll be sure to come back. thanks for sharing. and also This article gives the light in which we can observe the reality. this is very nice one and gives indepth information. thanks for this nice article... เว็บแทงบอล

The New Hampshire House of Representatives has approved an amended bill to establish a psilocybin advisory board to study pathways to allow patients to access the novel therapy—though lawmakers separately rejected an effort to revive separate legislation aimed at protecting gun rights for medical marijuana patients. Members took up the psilocybin and cannabis measures on Thursday, significantly scaling back the bipartisan psychedelics bill from Rep. Buzz Scherr (D) that would have in its initial form given certain patients legal access to psilocybin-assisted therapy. The amended version to create an advisory group to explore the issue passed the full chamber and now heads to the Senate for consideration. The medical marijuana and firearms legislation from Rep. Tom Mannion (R), meanwhile, was briefly considered on the floor, but a motion to take the bill off the table failed in a 81-270 vote. That proposal would make it so a person’s status as a registered medical cannabis patient in the state would not infringe on their right to purchase or possess guns under state law. The revised psilocybin bill represents a setback for advocates, as the House passed the initial version last month that would have created a regulatory pathway for patients with certain conditions to access the psychedelic for therapeutic use through a program overseen by the state Department of Health and Human Services (DHSS). Under House rules, the measure had to go back to the Finance Committee and then pass again in the full chamber in order to advance to the Senate. The committee deemed the bill inexpedient to legislate, and when it got the floor for the second time on Thursday, members overturned that recommendation and then adopted the major change that only contemplates a potential regulated access model instead, with an advisory board tasked with studying the issue. That dialed-back version ultimately passed. “The medical community has always recognized that patients exist with serious conditions that are very resistant to effective treatment,” a statement of purpose says. “Recently, research has begun to show that certain of those patients have had positive results with the closely supervised use of psilocybin for treatment.” “The purpose of this act is to study the feasibility of the creation of a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of psilocybin which that same provider has produced for a medical intervention,” the bill, HB 1809, says. On marijuana reform, the legislation from Mannion and bipartisan cosponsors, HB 1446, would preserve gun rights for medical cannabis patients in the state, reaffirming their right under the state constitution even if they continue to face a federal ban on possession or buying firearms persists. The U.S. Supreme Court is actively reviewing a case that could lift that prohibition after hearing oral arguments last month. “This bill ensures that our therapeutic cannabis patients are no longer treated as second-class citizens or differently from other patients being treated with different medications,” Rep. Billie Butler (D) said before the vote on the motion. Also this month, New Hampshire lawmakers effectively killed bills to legalize marijuana and allow the therapeutic use of psilocybin by not bringing them up for floor votes ahead of a key deadline. One bill from Rep. Jonah Wheeler (D) would have put a constitutional amendment on the state ballot to let voters decide if they want to legalize marijuana for adults 21 and older, allowing them to “possess a modest amount of cannabis for their personal use.” Members of the House Criminal Justice and Public Safety Committee took up that legislation in January. It was ultimately deemed inexpedient to legislate by a majority of the panel, but in New Hampshire all bills still have the opportunity to advance to the floor even with negative committee recommendations. Another cannabis legalization bill that didn’t get a floor vote in the House by deadline was HB 1235-FN from Rep. Jared Sullivan (D) and five bipartisan cosponsors. The measure was also designated as inexpedient to legislate by the Criminal Justice and Public Safety Committee. Sullivan also filed separate legislation this session that would have legalized adult-use cannabis through a regulated sales model, with additional provisions to provide relief for those who’ve previously been criminalized over marijuana. That bill already passed the House this year, but it was then promptly killed in the Senate. The House this month further declined to take up a Republican-led bill from Rep. Michael Moffett (R) that would have permitted the regulated use of psilocybin in a medically supervised setting. To qualify for psilocybin treatment, a patient 21 or older would have needed to be diagnosed with treatment-resistant depression, PTSD, substance misuse disorder, a terminal illness requiring end-of-life care or any other condition authorized by DHHS. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, Gov. Kelly Ayotte (R) has already threatened to veto any marijuana legalization bill that reaches her desk, though the constitutional amendment proposal would not require gubernatorial action. The governor said in August that her position on the reform would not change even if the federal government moved forward with rescheduling the plant. Since then, President Donald Trump has directed the attorney general to finalize the process of moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). At a committee meeting last year, Sullivan ultimately made a persuasive argument for advancing his legalization bill, pointing out that the House has repeatedly passed similar legislation and that the chamber should stand its ground, forcing the Senate and governor to again go on record with their opposition to a policy popular among voters. “We know where it’s going to go. Let’s send a virtue signal,” Sullivan said. “Let them be the ones that are pissing off voters who care about this.” In the Senate, the Judiciary Committee in January also took up a bill from Sen. Donovan Fenton (D) that would allow adults over the age of 21 to legally possess up to four ounces of cannabis in plant form and 20 grams of concentrated cannabis products, as well as other products containing no more than 2,000 milligrams of THC. Last June, the New Hampshire Senate voted to scrap compromise legislation that would have lowered the state’s criminal penalty for first-time psilocybin possession while also creating mandatory minimum sentences around fentanyl. As originally introduced, the legislation would have completely removed penalties around obtaining, purchasing, transporting, possessing or using psilocybin, effectively legalizing it on a noncommercial basis. However a House committee amended the bill before unanimously advancing it last March. Image element courtesy of Kristie Gianopulos. The post New Hampshire House Passes Scaled-Back Psilocybin Bill, While Rejecting Measure To Protect Medical Marijuana Patients’ Gun Rights appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

White House CBD meetings; AOC slams marijuana & psychedelics scheduling; TX lawmakers’ hemp & ibogaine reviews; Cannabis taxes op-ed Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The White House Office of Management and Budget has scheduled several additional meetings for this week about a CBD products compliance and enforcement policy that the Food and Drug Administration submitted for approval. Rep. Alexandria Ocasio-Cortez (D-NY) said the federal system for classifying marijuana and other drugs has “fallen short”—noting that “our law says that these drugs have zero medical application, but the science says something else.” “The wealth of medical research shows that these are potential treatments for treatment-resistant PTSD, traumatic brain injuries—but the schedule classification really prevents researchers from continuing to do work on this.” New York Gov. Kathy Hochul (D) is celebrating the five-year anniversary of marijuana legalization—touting $3.3 billion in sales, more than 600 operational licensed cannabis shops and achievements in promoting social equity and criminal justice reform. Texas’s lieutenant governor issued a mandate for the Senate Health and Human Services Committee to study the impact of cannabis and THC products during the legislative interim, while the House speaker directed the Public Health Committee to monitor implementation of legislation to establish a consortium to conduct ibogaine drug development clinical trials. LeafLink’s Rodney Holcombe argues in a new Marijuana Moment op-ed that calls to increase cannabis taxes from the New York Times editorial board and others “overlook how high effective tax burdens already are in many states.” “Higher taxes do not eliminate consumer demand. They simply change where consumers buy their cannabis.” / FEDERAL The Centers for Disease Control and Prevention published a study finding that an “analysis of 2015–2025 National Poison Data System data found an increase of approximately 1,200% in kratom-related exposure reports (from 258 to 3,434), including a marked surge in 2025.” Sen. Amy Klobuchar (D-MN) discussed her push to delay the federal recriminalization of hemp THC products. / STATES Former Texas Gov. Rick Perry (R) is reportedly writing a book about psychedelics aimed at a Christian audience. A Pennsylvania representative discussed his bill to strengthen medical cannabis testing protocols. Florida officials accused a petitioner for a marijuana legalization initiative of submitting nearly 1,600 fraudulent signatures. Michigan officials are facing another lawsuit challenging a new marijuana wholesale tax. New York’s top marijuana regulator discussed the five-year anniversary of legalization. Missouri regulators are seeking a new vendor to manage the state’s marijuana licensing and tracking program. The Arkansas Medical Marijuana Commission will meet on Thursday. The Rhode Island Cannabis Advisory Board will meet on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Oakland, California Cannabis Regulatory Commission will meet on Thursday. / INTERNATIONAL Germany’s interior minister called the country’s marijuana legalization policy a “shitty law.” South African officials gave lawmakers an update on efforts to develop a commercially viable cannabis and hemp industry. / SCIENCE & HEALTH A study found that “the adoption of [recreational cannabis legalization] in US states, beyond only [medical cannabis legalization], may help to reduce the size of illegal cannabis markets, or there may be shifting law enforcement seizure priorities in those states.” A review concluded that “MDMA-[assisted therapy] was associated with reductions in PTSD symptom severity and improvements in dissociative symptoms and global functioning.” / ADVOCACY, OPINION & ANALYSIS The Latino Cannabis Alliance is a new advocacy organization that aims to represent Latinos in the marijuana reform movement and industry. / BUSINESS Vireo Growth Inc. said its memorandum of understanding with The Scotts Miracle-Gro Company to acquire The Hawthorne Gardening Company LLC could close within five business days, subject to certain conditions. Illinois dispensaries sold $12.5 million worth of medical cannabis products in February. / CULTURE The Daily Show’s Josh Johnson joked about the Army’s move to loosen marijuana restrictions for new recruits. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Celebrating 5 years of legal cannabis in New York (Newsletter: March 31, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

In an era where online multiplayer can be stressful, the game's playful nature fosters a positive gaming environment by encouraging players to celebrate their victories and laugh at their exploits, as seen in monkey market.

With Tag Game, players can choose from a variety of mythical characters, each adding unique charm and excitement to the overall experience.

Kart Bros io is the best free racing game I've played. No intrusive ads during gameplay, just pure, focused racing. The instant browser access with no download makes Kart Bros io 2026 my go-to for a quick and satisfying session.https://www.kartbrosio.app/

The White House now scheduled a total of four meetings with cannabis industry and research stakeholders this week to discuss a proposed enforcement policy for CBD products. The Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) announced earlier this month that it plans to review yet-unpublished guidance titled “Cannabidiol (CBD) Products Compliance and Enforcement Policy” that was submitted by the Food and Drug Administration (FDA). Interested parties are able to request meetings to discuss the issue—and now four meetings have been set for April 1-2. David Heldreth, CEO of Panacea Plant Sciences, was the first to secure a meeting with OIRA, and he told Marijuana Moment last week he intends to use the opportunity to encourage FDA to develop more holistic guidance around CBD that goes beyond isolates of the cannabinoid. Since then, the White House has accepted requests for meetings to discuss the yet-to-be-published CBD rule with Trent Woloveck of the multi-state cannabis operator Jushi Holdings on Wednesday, as well as Mackie Barch of Story Cannabis and Iowa hemp farmer Earl Ramey on Thursday. All of this comes months before changes to federal hemp laws are set to significantly shake up the industry, with a ban on most consumable cannabinoid products containing THC taking effect in November. As part of the underlying law, FDA was tasked with publishing a list of known cannabinoids, but it missed a congressionally imposed deadline to fulfill that obligation and it’s unclear when that list will ultimately be furnished. Some have speculated that the enforcement policy guidance that OIRA is reviewing concerns the executive order President Donald Trump signed in December to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), which also included provisions directing the Centers for Medicare & Medicaid Services (CMS) to create a pathway for CBD health care coverage. To that end, CMS did recently shared new details about that plan, which would make it so patients enrolled in select insurance programs could have up to $500 of hemp-derived products covered each year beginning as early as Wednesday. The CBD-focused plan will also allow a certain amount of THC in products, but the agency said the planned rules are subject to change if federal hemp policy changes, as is currently expected under the law set to take effect in November. Participants would be required to ensure that CBD is sourced from “a legally compliant source and high-quality farm,” prepared as an oral solution and tested for cannabinoid content so that available products contain no more than 0.3 percent delta-9 THC by dry weight and up to 3 milligrams of total THC per serving. CMS said that centers participating in one of three models that receive substance access Beneficiary Engagement Incentives (BEI) will be able to “consult with eligible beneficiaries about the possible use of eligible hemp products to improve symptom control.” The new details about the rules for the CBD pilot program come weeks after a co-founder of the hemp company Charlotte’s Web, which has been collaborating with CMS, said the agency had already finalized its plans for federal health insurance coverage of cannabidiol. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — While CMS implemented an earlier final rule last April specifically stipulating that marijuana, as well as CBD that can be derived from federally legal hemp, are ineligible for coverage under its Medicare Advantage program and other services, the agency is now revising that policy. CMS had already announced certain changes as part of a rulemaking process that was unveiled late last year, affecting “marketing and communications, drug coverage, enrollment processes, special needs plans, and other programmatic areas” for insurance programs it oversees. One of those changes dealt with cannabidiol coverage. Meanwhile, with respect to the marijuana components of Trump’s December executive order, Attorney General Pam Bondi was directed to expeditiously finalize the proposal to reschedule cannabis, which would not federally legalize it but would remove certain research barriers and let state-licensed marijuana businesses take federal tax deductions they’re currently barred from under an Internal Revenue Service (IRS) code known as 280E. That rescheduling proposal remains pending, however. The post White House Schedules More Meetings On Cannabis Product Enforcement Policy From FDA For This Week appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The governor of New York is marking the five-year anniversary of adult-use marijuana legalization in the state, touting $3.3 billion in retail sales, the opening of more than 600 licensed cannabis shops and achievements in promoting social equity in the industry while taking steps to mitigate the illicit market. In a press release on Friday, Gov. Kathy Hochul (D) said “New York committed to building a cannabis market rooted in equity, safety, and opportunity” when the state enacted the Marihuana Regulation and Taxation Act five years ago. “We are creating new pathways for small businesses while aggressively shutting down illicit shops that threaten public safety and undermine our legal market,” the governor, who has helped lead the implementation of the cannabis reform and celebrated its milestones along the way, said. “Our focus is clear: protect consumers, support legal businesses, and ensure this industry grows the right way.” In addition to seeing $3.3 billion in recreational marijuana sales over the past half-decade, New York officials have also licensed 2,161 cannabis businesses across the supply chain, including 610 retailers that are now operational. The 600th marijuana shop, Pure Blossoms, recently opened its doors in Manhattan. “New York’s cannabis market is demonstrating that growth and equity are not mutually exclusive,” Office of Cannabis Management (OCM) Acting Executive Director John Kagia said. “With more than $3 billion in sales, a majority of licenses held by Social and Economic Equity applicants, and a rapidly expanding retail footprint, the State is building a market that is both economically viable and intentionally inclusive.” “These outcomes reflect a deliberate approach to ensuring long-term stability, accountability, and opportunity across the industry as we continue to strengthen the market and expand access in the years ahead,” he said. All told, more than half (56 percent) of adult-use marijuana licensees have go to Social and Economic Equity (SEE) applicants, which surpasses the state’s statutory goal. Those SEE licensees include 57 percent that have gone to women-owned businesses and 51 percent to minority-owned businesses. Also with respect to equity achievements, the state is promoting the fact that more than 400,000 cannabis-related convictions are been deemed eligible for expungement, and over 200,000 have already been sealed. Another 107,000 cases have been “suppressed pending sealing,” and nobody is currently incarcerated in state prison for a marijuana-related offense alone, the governor’s release says. Further, the state has distributed $5 million in funding for community reinvestment through a fund supported by marijuana tax dollars, and another $5 million is currently available in the fund that aims to promote youth development, workforce training, housing opportunities and public health projects for people in areas disproportionately impacted by criminalization. The MRTA “centered on equity, economic opportunity and restorative justice,” Assembly Majority Leader Crystal Peoples-Stokes (D), who a key champion of adult-use legalization in the state, said. “These core principles remain my priority as the legal cannabis market continues to mature.” “We, as legislators, and leaders in the state, have a duty to take steps to correct the harm that was done by the War on Drugs. As the adult-use cannabis market in New York State continues to grow, we must not lose sight of the equity tenants of MRTA,” she said. “New York State’s cannabis market is setting the standard that the rest of the country should follow and I am immensely proud of that.” Sen. Erik Bottcher (D) said that, five years into the state’s legalization experience, “we’re seeing small businesses and entrepreneurs finding their footing as well as and investments that are reaching communities that were disproportionately impacted in the past.” “The opening of new, licensed dispensaries and the shutdown of illegal dispensaries reflects that forward momentum,” he said. “Thank you to Governor Hochul for ensuring that as the industry continues to grow we remain focused on supporting responsible operators and customers alike.” In January, meanwhile, New York officials released a set of reports providing a 2025 end-of-year status update on the evolution of the state’s medical and adult-use marijuana markets—touting record sales, revenue hauls for state coffers, licensing approvals, equity initiatives and more. The OCM annual report also notes that Hochul signed legislation into law that expands the state’s medical cannabis program by improving patient access and “updating the program framework to better meet patient needs statewide.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, New York senators recently approved a bill related to reciprocity for out-of-state medical marijuana patients and the availability of pre-rolled joints in the medical cannabis market—even though the state has already enacted those reforms separately. Last month, the sponsor of the bill separately introduced legislation that would allow New York liquor and wine stores to obtain a permit to sell low-dose cannabis-infused drinks at their businesses. Also, the governor of New York last month signed legislation into law that revises zoning requirements for licensed marijuana businesses, granting more flexibility to retailers located within certain distances of schools and places of worship. In January, New York officials released a set of reports providing a 2025 end-of-year status update on the evolution of the state’s medical and adult-use marijuana markets—touting record sales, revenue hauls for state coffers, licensing approvals, equity initiatives and more. Also, the governor of New York last month signed legislation into law that revises zoning requirements for licensed marijuana businesses, granting more flexibility to retailers located within certain distances of schools and places of worship. Photo courtesy of Philip Steffan. The post New York Governor Marks Five-Year Anniversary Of Marijuana Legalization, With Over $3.3 Billion In Sales And 610 Licensed Retailers appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Higher taxes do not eliminate consumer demand. They simply change where consumers buy their cannabis.” By Rodney Holcombe, LeafLink In recent piece, The New York Times editorial board called for a federal tax on cannabis and urged states to raise their own taxes to “dollars per joint, not cents.” That argument assumes cannabis is lightly taxed today—but across the country, the opposite is true. Taxes on legal cannabis are higher than almost every industry in the United States and have generated nearly $25 billion since adult-use sales commenced in 2014. Despite these rates, efforts to increase cannabis levies are continuing to gain steam. In 2025 alone, Maryland, Minnesota, Maine, Ohio, Michigan and California attempted to raise or expand cannabis taxes. This year, Colorado and Oklahoma are looking to do the same. Many of those proposals emerged as lawmakers confronted budget shortfalls and the expiration of federal pandemic aid. Cannabis has increasingly been treated as an untapped source of revenue. In several large markets, cannabis taxes are layered on top of one another. Excise taxes are combined with state sales taxes, wholesale taxes, local taxes and, in some cases, potency-based taxes. In states such as Illinois, Michigan and Washington, the effective burden can exceed 40 percent. This is in addition to the federal tax burden cannabis businesses carry under §280E, which limits their ability to deduct ordinary operating expenses. These structures are straining the legal market. High tax burdens are contributing to business closures (particularly among smaller operators) and pushing many consumers to the illicit market. According to publicly available data, several highly taxed states, including California, Colorado, Illinois, and Washington, have experienced year-over-year declines in adult-use sales and industry job losses in recent years. At the same time, the illicit markets across these states remain entrenched. In California, one of the nation’s oldest legal cannabis markets, estimates suggest that roughly 60 percent of sales still occur outside the regulated system. Higher taxes do not eliminate consumer demand. They simply change where consumers buy their cannabis. Licensed businesses pay for testing, packaging, compliance systems, labor and sometimes local licensing. Unregulated sellers do not. When the legal price rises too far above the illicit alternative, price-sensitive consumers shift accordingly. That weakens the regulated market that legalization was intended to build. When tax increases take effect, the impact shows up quickly in wholesale pricing pressure, retailer margin compression, and shifts in purchasing behavior. The cannabis industry is still new, but data tell us that the type of tax matters as much as the rate. THC-based potency taxes have created compliance and administrative challenges in states such as Connecticut and Illinois. Because liability is tied to measured THC content rather than price, minor variations in laboratory testing can alter tax obligations. That adds cost and uncertainty for operators. It also influences pricing in ways that do not necessarily advance public health goals. New York eliminated its potency tax and replaced it with a distributor-level excise tax after determining the structure was not working as intended. States with lower and simpler effective tax structures have generally shown more stable performance. Markets with competitive total burdens and several years of operating history have tended to demonstrate steadier sales and job growth. While federal prohibition and hemp-derived THC competition complicate conditions nationwide, tax policy remains fully within state control. Recent developments illustrate how sensitive these markets are to tax changes. In 2025, San Diego raised its local cannabis tax to 10 percent, double the rate when it was first introduced. Data show that the tax brought in less revenue than projected, likely as a result of consumers seeking out alternate channels for purchasing products. In Michigan, a 24 percent wholesale tax took effect this year atop the existing excise and sales taxes. The state’s January 2026 sales revenue decreased 16 percent from December and falls below January 2025 levels. Cannabis tax revenue funds many meaningful programs across the country, but these programs depend on a functional legal market that can actually generate that revenue. If tax rates push consumers back to the illicit market, this revenue simply won’t materialize. The issue is not whether cannabis should be taxed. It is whether tax systems are calibrated in a way that allows the legal market to function as intended. Calls to raise taxes to “dollars per joint” overlook how high effective tax burdens already are in many states. When licensed operators are forced to compete with illicit sellers, higher taxes risk slowing the transition of consumers into regulated channels and weakening this still nascent industry. If policymakers are evaluating the performance of legalization or creating a framework for a new market, tax design should be a critical part of that conversation. Excessive and complex tax systems make it harder for licensed businesses to compete and for states to achieve their public health, safety, and revenue goals. Rodney Holcombe is the vice president of Public Policy and Communications at LeafLink. The post Too High To Thrive: Excessive Cannabis Taxes Are Undermining Legal Markets (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Texas Senate and House leaders are directing lawmakers to study issues related to cannabis products and psychedelic therapy during the legislature’s interim in preparation for a new session scheduled to begin in early 2027. Lt. Gov. Dan Patrick (R), who oversees the Senate, pushed to pass legislation last session to ban hemp THC products. The legislation was approved by lawmakers but was later vetoed by Gov. Greg Abbott (R). But Patrick isn’t giving up. In his list of 2026 interim legislative charges released on Friday, he’s directing the Senate Health and Human Services Committee. Under a heading titled, “Addressing Societal Impacts of THC Product Consumption,” the lieutenant governor charged the panel to “study the impact of THC on increased health care costs, mental health emergency detentions, and the risk of being diagnosed with a THC-induced psychotic disorder.” The committee should “make recommendations to decrease health care and criminal justice costs,” the directive says. My statement announcing 2026 Interim Charges to the Texas Senate. To read the interim charges, click here: https://t.co/KtW2BUX7Rx#txlege pic.twitter.com/9fMdjiXvMX — Office of the Lieutenant Governor Dan Patrick (@LtGovTX) March 27, 2026 Separately, House Speaker Dustin Burrows (R) is directing his chamber’s Public Health Committee to spend time before the next session monitoring the “implementation and associated rulemaking” for legislation enacted last year to support clinical trials aimed at developing the psychedelic ibogaine into a legal prescription medicine to treat substance use disorders and other mental health conditions. The list of interim charges issued by the speaker on Thursday notes that the bill that Abbott signed into law relates to “the establishment of a consortium to conduct United States Food and Drug Administration’s drug development clinical trials with ibogaine to secure the administration’s approval of the medication’s use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.” Today, I issued interim charges for House committees of the 89th Texas Legislature to guide our work ahead of the next legislative session in 2027. These priorities build on our recent progress, strengthen accountability in government, reduce inefficiencies, and ensure key… pic.twitter.com/woyc1E0xjv — Dustin Burrows (@Burrows4TX) March 26, 2026 Earlier this month, the Texas Department of State Health Services (DSHS) adopted new hemp product rules that will effectively ban smokable hemp THCA flower. Specifically, the agency approved language requiring hemp products to be tested for “total THC” content, including THCA, which means most cannabis flower would be considered non-compliant with limitations imposed under state law. Meanwhile this month, Texas voters approved a marijuana legalization question that appeared on the state’s Democratic primary ballot. As part of the primary election, each major party was able to place several non-binding propositions on the ballot that allow voters show how they feel on key issues. The Texas Democratic Party used one of its propositions to find out where the electorate stands on legalizing cannabis and whether past convictions should be expunged. For what it’s worth, a statewide poll released last month found that Texas voters don’t like how state leaders and lawmakers have handled marijuana and THC policy issues. In the survey, a plurality of voters (40 percent) said they disapprove of how their elected officials have approached the issue, according to the survey. Just 29 percent said they approve of how cannabis issues have been handled, while 31 percent said they didn’t have an opinion one way or another. A separate poll released last year found that a plurality of Texas voters want the state’s marijuana laws to be made “less strict.” And among the legislative items lawmakers considered during recent special sessions, voters say a proposal to address hemp regulations was among the least important. With respect to ibogaine under the bill the governor signed, Texas will retain a commercial interest in “all intellectual property that may be generated over the course of the drug development clinical trials,” the legislation says, with an aim of making the state a hub for “ibogaine-related biomedical research, development, treatment, manufacturing, and distribution.” A quarter of revenue taken in by the state from any resulting intellectual property would fund veterans programs. Along with the legislation’s goal of winning federal Food and Drug Administration (FDA) approval as a clinical treatment, the bill says it also seeks “a breakthrough therapy designation for ibogaine”—a designation FDA gives to emerging treatment options that haven’t yet secured agency approval to treat a particular condition. The post Texas Lawmakers Will Study Cannabis And Psychedelics Issues Under New Orders From Senate And House Leaders appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I would like to say that this blog really convinced me to do it! Thanks, very good post. 오피스타

What a thrilling post, you have pointed out some excellent points, I as well believe this is a superb website. I have planned to visit it again and again. live toto

What a thrilling post, you have pointed out some excellent points, I as well believe this is a superb website. I have planned to visit it again and again. pestoto 4d

Rep. Alexandria Ocasio-Cortez (D-NY) tore into the current U.S. drug scheduling system on Thursday—making the case that placing substances like marijuana and LSD in the most restrictive category runs counter to evidence showing their medical potential, hinders research and is associated with criminal penalties that haven’t effectively prevented harms from substance misuse. In some cases, the congresswoman said during a hearing before the House Energy & Commerce Health Subcommittee, classifying drugs as Schedule I under the Controlled Substances Act (CSA) can exacerbate the overdose crisis, leading to the introduction of new, sometimes more dangerous drugs into the illicit marketplace. The panel on Thursday took testimony on a variety of bills aimed at curbing overdose deaths and responding to emerging public health threats posed by illegal drugs such as xylazine and other opioid-like synthetics that are often more potent than the analogues that came before them. Ocasio-Cortez said it was time to “take a step back” and “really explore and examine the scheduling system in the United States as a whole and really how we think about this,” directing her questions to Nabarun Dasgupta, a senior scientist at the University of North Carolina who served as an expert witness for the hearing. Our current drug scheduling system in the U.S. does little to deter drug abuse or overdose rates, but instead hinders research and unfairly criminalizes communities. We need to invest in actual solutions like prevention, treatment, and recovery. pic.twitter.com/CNkfaN795W — Rep. Alexandria Ocasio-Cortez (@RepAOC) March 26, 2026 “We’re often trying to slot in certain substances into our scheduling [and] end up playing a lot of whack-a-mole,” the congresswoman said. “Once you schedule one substance, people then start finding alternatives—and before you know it, people are then starting to overdose on entirely new substances that we didn’t even know existed a couple of years ago.” “In theory, Schedule I drugs are supposed to have no potential for medical use and high risk for abuse and addiction, correct?” she asked Dasgupta, who affirmed that was the case. “There are also specific penalties tied to each schedule. Once a drug gets scheduled, the penalties for possessing that drug can change overnight,” Ocasio-Cortez said. “And so when we look back at the point of scheduling, in about 1970 or so, Congress created this system to try to deter the use of dangerous drugs by applying criminal penalties to the possession of those drugs and scheduling was also intended to ensure safety when these drugs are used in clinical or research settings.” “Now, since this system was established more than 50 years ago, we’ve seen how it’s fallen short. We’ve endured the war on drugs, and we’ve also had a lot of limitations in medical research,” she said before asking the expert to provide examples of drugs currently classified as Schedule I under the CSA. Dasgupta pointed to marijuana, LSD and MDMA, and Ocasio-Cortez followed up by asking for his opinion on whether those three substances meet the definition of having “zero potential medical application.” “I think the medical literature is clear that they do have clinical benefits,” Dasgupta said. The congresswoman had him repeat that point, clarifying that its his assessment that “right now our law says that these drugs have zero medical application, but the science says something else.” “That’s right,” he said. Ocasio-Cortez added that “the wealth of medical research shows that these are potential treatments for treatment-resistant PTSD, traumatic brain injuries—but the schedule classification really prevents researchers from continuing to do work on this, correct?” The scientist again answered in the affirmative. Opponents might counter that narrative by arguing that “people are overdosing on some of these substances, so we still need to schedule them,” the congresswoman said. “But has adding criminal penalties successfully reduced overdose deaths?” Dasgupta answered by pointing to an examples out of Florida, where the state placed xylazine in Schedule I of their own controlled drugs list but then saw overdose deaths from xylazine increase from about 3,700 per year to 6,400 per year. That goes to show that simply scheduling a drug is “not a panacea,” he said. Ocasio-Cortez went on to say that “increasing the scheduling is becoming medically prohibitive for treatments, but then also adding the criminal penalties has not only not reduced overdose, but in the state of Florida, it’s doubled them.” “But I think we’re all still here on the same purpose, right? We want to make sure that we’re protecting people and doing what we can,” she said, asking the witness whether he’s aware of “any methods…that can help us make progress on this.” Dasgupta said, “I mean, I think scheduling does have an important role. I think there just needs to be a lot more flexibility to keep the science in line with the regulatory process. That’s the bottom line.” Of the three Schedule I drugs that the scientist cited at the hearing, the Food and Drug Administration (FDA) has already signaled that they each hold medical potential, with one LSD-like substance, MM120, and the main compound of ecstasy, MDMA, receiving breakthrough therapy status to promote research that could lead to drug development. For marijuana, its time in Schedule I may be coming to an end. After a years-long scientific review led by FDA, former Attorney General Merrick Garland ultimately signed a proposed rule to move cannabis to Schedule III of the CSA. That process wasn’t completed by the end of the Biden administration that initiated it, but President Donald Trump in December signed an executive order directing the current attorney general, Pam Bondi, to expeditiously finalize that rule. As Rep. Steve Cohen (D-TN) noted in a letter sent to Bondi on Friday, however, marijuana remains in Schedule I even three months after the president issued that directive. The congressman is therefore seeking an update from DOJ on the status of its rulemaking. The post AOC Slams Federal Drug Laws That Restrict Marijuana And Psychedelics Despite Their Medical Value appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

My spouse and i shocked while using investigation anyone created to choose this certain release outstanding. Amazing task! 屋根補修

Bipartisan Senate psychedelics bill; MS gov vetoes medical marijuana expansion; IN gov talks legalization; Poll: Cannabis use isn’t immoral Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Rep. Steve Cohen (D-TN) sent a letter pressing Attorney General Pam Bondi and Drug Enforcement Administration Administrator Terrance Cole for an update on where marijuana rescheduling stands three months after President Donald Trump issued an order directing it be completed in “the most expeditious manner.” The letter also asks about the Department of Justice missing a statutory deadline to issue guidelines on easing research barriers into Schedule I drugs like cannabis and psychedelics. Sens. Tim Sheehy (R-MT), Tammy Duckworth (D-IL), Ruben Gallego (D-AZ) and John Boozman (R-AR) filed a bill to create a new Department of Veterans Affairs office that would promote research on psychedelics and assist in reviewing scheduling status of drugs like psilocybin, ibogaine and MDMA. Mississippi Gov. Tate Reeves (R) vetoed two bills to expand medical cannabis access but signed separate legislation to support research on the psychedelic ibogaine. Indiana Gov. Mike Braun (R) blamed Republican legislative leaders for refusing to reform marijuana laws while “over half of Hoosiers probably smoke it illegally”—but said he thinks the “crescendo will rise” in the call for legalization. A new poll shows that a majority of Americans across every age, gender, religion and political demographic agree that using marijuana is not morally wrong—but that Republicans are still twice as likely as Democrats to say consuming cannabis is a moral no-no. Kansas’s attorney general and other law enforcement officials are being sued by smoke and vape shops that say they failed to distinguish between legal hemp and illegal cannabis products during recent raids on their businesses. Here’s a look at what newly enacted restrictions on marijuana and hemp products mean for consumers and businesses. / FEDERAL The Drug Enforcement Administration posted another profile of one of its special agents. Rep. Alexandria Ocasio-Cortex (D-NY) is being accused of improperly spending nearly $19,000 in campaign funds on a therapist who specializes in ketamine therapy. The House bill to provide a pathway for patients to access Schedule I drugs got one new cosponsor for a total of 17. / STATES Utah Gov. Spencer Cox (R) signed bills to amend medical cannabis rules. Minnesota Gov. Tim Walz (D) signed a bill to allow businesses manufacturing lower-potency hemp edibles to temporarily continue using out-of-state testing facilities. The Oklahoma House of Representatives rejected a bill to allow counties to tax medical cannabis. The Pennsylvania Supreme Court ruled that a cannabis trade association does not have standing to challenge a local court’s rule restricting people who are on probation from using medical cannabis. California regulators announced a recall of marijuana products due to inner packaging that is missing required labeling. New Jersey’s top cannabis regulator is stepping down. New Mexico regulators released draft psilocybin program rules. The New Jersey Cannabis Regulatory Commission will meet on Tuesday. The New York Cannabis Control Board will meet on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL A San Francisco, California supervisor is pushing a proposal to halt funding for new permanent supportive housing facilities that are unwilling to evict residents over drug use. / INTERNATIONAL A former German health minister tweeted, “Just as (also predicted by me) before: cannabis consumption does not rise with legalization, and the crime rate drops dramatically. Legalization was right. Stamping young adults as criminals for cannabis consumption was simply unfair.” / SCIENCE & HEALTH A review concluded that “exogenous cannabinoids show beneficial effects in pre-clinical [inflammatory bowel disease] models, likely through anti-inflammatory, antioxidant, and barrier-enhancing mechanisms.” A study “demonstrates that psilocybin reduces aggression and activity in an emerging fish model, adding to the evidence supporting its potential as a therapeutic agent for future clinical translation.” / BUSINESS iAnthus Capital Holdings, Inc. reported quarterly revenue of $35.3 million and a net loss of $14.1 million. Jushi Holdings Inc. completed refinancing of its former senior secured credit facility and its former second lien credit facility through the issuance of a $160 million senior secured term loan. / CULTURE Bob Marley’s heirs are suing Tilray Brands Inc. over millions in payments tied to a deal licensing his name, image and likeness. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post DOJ cannabis rescheduling update requested by congressman (Newsletter: March 30, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The game isn't just about clicking; Cookie Clicker also requires smart investment strategies in construction and skills to achieve hidden accomplishments, helping you become the richest cookie tycoon in game history.

Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. StreamEast Live

Informative article very good approach towards data you provides good work. May all your dreams come true and may you find happiness and success in all your endeavors. Best wishes to you always. Estatus Becas Benito Juárez

Informative article very good approach towards data you provides good work. May all your dreams come true and may you find happiness and success in all your endeavors. Best wishes to you always. 블랙툰

“The lawsuit is a tactic to distract from the fact that Indy Vapes and Abilene Vape and CBD made a business decision to ignore state law.” By Maya Smith, Kansas Reflector Three smoke and vape shops are suing the state of Kansas, accusing officials of Fourth Amendment violations in a series of October raids. The plaintiffs have filed suit against KBI director Tony Mattivi, Attorney General Kris Kobach (R), KBI agents, local law enforcement and county attorneys. They allege illegal search and seizure and defective warrants. The KBI and local law enforcement executed raids late last year on smoke and vape shops in Concordia, Independence, Abilene, McPherson, Pratt, Salina, Topeka and Wichita. The raids were planned in an effort to end lax enforcement of laws against marijuana and THC in Kansas, according to Kobach at a press conference held during the raids. The lawsuit claims officers seized hemp-derived products without distinctions in the warrants between legal and illegal hemp products under Kansas law. The smoke and vape shops say the warrants were defective for not acknowledging that types of hemp-derived products are legal within Kansas, with the warrant for Indy Vapes in Independence stating all derivatives of THC are contraband. The Kansas Controlled Substance Act says industrial hemp and hemp-derived products are legal and are not controlled substances if they have less than a 0.3 percent concentration of THC. The plaintiffs say they sell legal hemp products and purchase those products from established wholesalers. Kobach’s office did not respond to repeated requests for comment for this story. The shops said they lost thousands of dollars in inventory and that the seized inventory was likely destroyed. Mattivi said at a press conference held during the raids that seized products were sent to labs by the KBI for private testing. According to the lawsuit, officers told employees not to film them, covered windows from the inside and unplugged the store’s internet and in-store security cameras. “The lawsuit is a tactic to distract from the fact that Indy Vapes and Abilene Vape and CBD made a business decision to ignore state law, and now want to blame law enforcement for what they knew was a likely consequence,” according to a statement from the KBI. “We will defend our responsibility to enforce the laws of Kansas.” The KBI said warrants executed by agents gave them the authority to seize illegal products and contraband. The statement did not address agents interfering with recording. This story was first published by Kansas Reflector. Photo elements courtesy of rawpixel and Philip Steffan. The post Kansas Officials Are Being Sued Over Raids Against Hemp Businesses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for a very interesting blog. What else may I get that kind of info written in such a perfect approach? I’ve a undertaking that I am simply now operating on, and I have been at the look out for such info. togel online

You make so many great points here that I read your article a couple of times. Your views are in accordance with my own for the most part. This is great content for your readers. togel online

Thank you because you have been willing to share information with us. we will always appreciate all you have done here because I know you are very concerned with our. bandar lotre online